Type 1 ILCs are characterized by particular surface markers such as CD127- and CD49a+ and by their ability to produce granzyme B. These type 1 ILCs expanded in mouse mammary pre-cancerous lesions and they exhibited potent cytotoxic activities against tumor cells, limiting tumor growth. Here, GZMB is linked to neoplasm.